Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 506-507, Issue , 2002, Pages 65-77

  Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Aromatic amines; Colon cancer; Heterocyclic amines; N Acetylation polymorphism; Single nucleotide polymorphisms; Urinary bladder cancer

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE; CARCINOGEN; HETEROCYCLIC AMINE;

ACETYLATION; ACETYLATOR PHENOTYPE; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLON CANCER; DETOXIFICATION; GENETIC POLYMORPHISM; GENOTYPE; METABOLISM; MOLECULAR GENETICS; NOMENCLATURE; NONHUMAN; OCCUPATIONAL EXPOSURE; PHENOTYPE; POPULATION; PRIORITY JOURNAL; PROTEIN FUNCTION;

ACETYLATION; ACETYLTRANSFERASES; AMINES; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; ISOENZYMES; MOLECULAR BIOLOGY; NEOPLASMS, EXPERIMENTAL; POLYMORPHISM, GENETIC;

RODENTIA;

EID: 0037201542     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(02)00153-7     Document Type: Article

References (39)

1. Hein D.W., Grant D.M., Sim E. Update on consensus N-acetyltransferase gene nomenclature. Pharmacogenetics. 10:2000;291-292.
2. Hein D.W. A new model for toxic risk assessments: construction of homozygous rapid and slow acetylator congenic Syrian hamster lines. Toxicol. Methods. 1:1991;44-52.
3. Hein D.W., Doll M.A., Rustan T.D., Gray K., Ferguson R.J., Feng Y. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Toxicol. Appl. Pharmacol. 124:1994;16-24.
4. Leff M.A., Epstein P.N., Doll M.A., Fretland A.J., Devanaboyina U.-S., Rustan T.D., Hein D.W. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther. 290:1999;182-187.
5. Hein D.W., Rustan T.D., Bucher K.D., Furman E.J., Martin W.J. Extrahepatic expression of the N-acetylation polymorphism towards arylamine carcinogens in tumor target organs of an inbred rat model. J. Pharmacol. Exp. Ther. 258:1991;232-236.
6. Hein D.W., Rustan T.D., Bucher K.D., Miller L.S. Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus. J. Pharmacol. Exp. Ther. 259:1991;699-704.
7. Feng Y., Jiang W., Deitz A.C., Hein D.W. 3,2′-Dimethyl-4-aminobiphenyl-DNA adduct formation in tumor-target and non-target organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol. Appl. Pharmacol. 140:1996;315-321.
8. Jiang W., Feng Y., Hein D.W. Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2′-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol. 156:1999;187-194.
9. Shirai T., Sano M., Tamano S., Takashasi S., Hirose M., Futauchi M., Hasegawa R., Imaida K., Matsumoto K., Wakabayashi K., Sugimura T., Ito N. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res. 57:1997;195-198.
10. Shirai T., Cui L., Takahashi S., Futakuchi M., Asamot M., Kato R., Ito N. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett. 143:1999;217-221.
11. Feng Y., Wagner R.J., Fretland A.J., Becker W.K., Cooley A.M., Pretlow T.P., Lee K.J., Hein D.W. Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2′-dimethyl-4-aminobiphenyl. Cancer Res. 56:1996;527-531.
12. Paulsen J.E., Steffensen I.L., Namork E., Hein D.W., Alexander J. Effect of acetylator genotype on 3,2′-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Carcinogenesis. 17:1996;459-465.
13. Feng Y., Fretland A.J., Jiang W., Becker W.K., Hein D.W. Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2′-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol. 147:1997;56-62.
14. Purewal M., Velasco M., Fretland A.J., Hein D.W., Wargovich M.J. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine induces a higher number of aberrant crypt foci in Fischer 344 (rapid) than Wistar Kyoto (slow) acetylator rats. Cancer Epidemiol. Biomarkers Prev. 9:2000;529-532.
15. Fretland A.J., Doll M.A., Leff M.A., Hein D.W. Functional characterization of nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenetics. 11:2001;511-520.
16. A.J. Fretland, M.A. Doll, Y. Zhu, L. Smith, M.A. Leff, D.W. Hein, Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: Implications for cancer predisposition, Cancer Detect. Prev. 26 (2002) 10-14.
17. *10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55:1995;5226-5229.
18. Hein D.W., McQueen C.A., Grant D.M., Goodfellow G.H., Kadlubar F.F., Weber W.W. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab. Dispos. 28:2000;1425-1432.
19. Hein D.W., Doll M.A., Fretland A.J., Webb S.J., Xiao G.H., Devanaboyina U.-S., Nangju N.A., Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9:2000;29-42.
20. de Leon J.H., Vatsis K.P., Weber W.W. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol. Pharmacol. 58:2000;288-299.
21. Butcher N.J., Ilett K.F., Minchin R.F. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol. Pharmacol. 57:2000;468-473.
22. Weber W.W., Hein D.W. N-Acetylation pharmacogenetics. Pharmacol. Rev. 37:1985;25-79.
23. Fretland A.J., Leff M.A., Doll M.A., Hein D.W. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics. 11:2001;207-215.
24. Y. Zhu, M.A. Doll, D.W. Hein, Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2, Biol. Chem. 383 (2002) 983-987.
25. Hein D.W., Doll M.A., Rustan T.D., Ferguson R.J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 55:1995;3531-3536.
26. Brockmoller J., Cascorbi I., Kerb R., Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione-S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56:1996;3915-3925.
27. Okkels H., Sigsgaard T., Wolf H., Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomarkers Prev. 6:1997;225-231.
28. Filiadis I.F., Georgiou I., Alamanos Y., Kranas V., Giannakopoulos X., Lolis D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J. Urol. 161:1999;1672-1675.
29. Cartwright R.A., Glashan R.W., Rogers H.J., Ahmad R.A., Hall D.B., Higgins E., Kahn M.A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 2:1982;842-845.
30. D.W. Hein, M.A. Leff, N. Ishibe, R. Sinha, J. Berlot, J. Frame, H.A. Frazier, M.A. Doll, M.C. Weinrich, N.E. Caporaso, Slow N-acetyltransferase and null glutathione-S-transferase genotypes and prostate cancer risk, in: Proceedings of the Joint Meeting of the American Society for Biochemistry and Molecular Biology/American Society for Pharmacology and Experimental Therapeutics, #LB64, Boston, MA, June 2000.
31. D.W. Hein, M.A. Leff, N. Ishibe, R. Sinha, H.A. Frazier, M.A. Doll, G.H. Xiao, M.C. Weinrich, N.E. Caporaso, Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1* 10) in combination with slow N-acetyltransferase 2 genotypes in a pilot case control study. Environ. Mol. Mutagen. 40 (2002) in press.
32. Taylor J.A., Umbach D.M., Stephens E., Castranio T., Paulson D., Roberson C., Mohler J.L., Bell D.A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene exposure three-way interaction. Cancer Res. 58:1998;3603-3610.
33. *10. Cancer Res. 61:2001;5051-5056.
34. Hein D.W. N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol. Lett. 112/113:2000;349-356.
35. Brockton N., Little J., Sharp L., Cotton S.C. N-Acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am. J. Epidemiol. 151:2000;846-861.
36. Ishibe N., Sinha R., Hein D.W., Kulldorff M., Strickland P., Fretland A.J., Chow W.-H., Kadlubar F.F., Lang N.P., Rothman N. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics. 12:2002;145-150.
37. Sinclair J.C., Sandy J., Delgoda R., Sim E., Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 7:2000;560-564.
38. Lima-Rodrigues F., Delomenie C., Goodfellow G.H., Grant D.M., Dupret J.M. Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. Biochem. J. 356:2001;327-334.
39. Lima-Rodrigues F., Dupret J.M. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem. Biophys. Res. Commun. 291:2002;116-123.